Microarray patches: scratching the surface of vaccine delivery

References

• Azad N, Rojanasakul Y. Vaccine delivery–current trends and future. Curr Drug Deliv. 2006 Apr;3(2):137–146. doi: 10.2174/156720106776359249
   PubMedGoogle Scholar
• Lee YH, Harris RC, Oh HW, et al. Vaccine-related errors in reconstitution in South Korea: a National Physicians’ and nurses’ survey. Vaccines. 2021;9(2):117. doi: 10.3390/vaccines9020117
   PubMed Web of Science ®Google Scholar
• Auewarakul P, Kositanont U, Sornsathapornkul P, et al. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine. 2007 Jan 8;25(4):659–663. doi: 10.1016/j.vaccine.2006.08.026
   PubMed Web of Science ®Google Scholar
• Brown H, Kasel JA, Freeman DM, et al. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis. 1977 Dec;136(Suppl):S466–71. doi: 10.1093/infdis/136.Supplement_3.S466
   PubMedGoogle Scholar
• Chiu SS, Peiris JS, Chan KH, et al. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics. 2007 Jun;119(6):1076–1082. doi: 10.1542/peds.2006-3176
   PubMed Web of Science ®Google Scholar
• Fishbein DB, Pacer RE, Holmes DF, et al. Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study. J Infect Dis. 1987 Jul;156(1):50–55. doi: 10.1093/infdis/156.1.50
   PubMed Web of Science ®Google Scholar
• Halperin W, Weiss WI, Altman R, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health. 1979 Dec;69(12):1247–1251. doi: 10.2105/AJPH.69.12.1247
   PubMed Web of Science ®Google Scholar
• Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis. 1979 Aug;140(2):234–238. doi: 10.1093/infdis/140.2.234
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004 Nov 25;351(22):2295–2301. doi: 10.1056/NEJMoa043540
   PubMed Web of Science ®Google Scholar
• Khawplod P, Wilde H, Sirikwin S, et al. Revision of the Thai Red cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine. 2006 Apr 12;24(16):3084–3086. doi: 10.1016/j.vaccine.2006.01.051
   PubMed Web of Science ®Google Scholar
• Quiambao BP, Dimaano EM, Ambas C, et al. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine. 2005 Feb 25;23(14):1709–1714. doi: 10.1016/j.vaccine.2004.09.027
   PubMed Web of Science ®Google Scholar
• Warrell MJ, Nicholson KG, Warrell DA, et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet. 1985 May 11;1(8437):1059–1062. doi: 10.1016/S0140-6736(85)92367-0
   PubMed Web of Science ®Google Scholar
• Samuel BU, Cherian T, Sridharan G, et al. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet. 1991 1991/Aug/10;338(8763):343–344. doi: 10.1016/0140-6736(91)90480-D
   PubMed Web of Science ®Google Scholar
• Arnou R, Eavis P, Pardo JR, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, phase III trial. Hum Vaccin. 2010 Apr;6(4):346–354. doi: 10.4161/hv.6.4.10961
   PubMed Web of Science ®Google Scholar
• Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009 Dec 9;27(52):7304–7312. doi: 10.1016/j.vaccine.2009.10.033
   PubMed Web of Science ®Google Scholar
• Atmar RL, Patel SM, Keitel WA. Intanza(®): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010 Dec;9(12):1399–1409. doi: 10.1586/erv.10.134
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004 Nov 25;351(22):2286–2294. doi: 10.1056/NEJMoa043555
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 2009 Apr 2;7(1):13. doi: 10.1186/1741-7015-7-13
   PubMedGoogle Scholar
• Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008 Sep 1;198(5):650–658. doi: 10.1086/590434
   PubMed Web of Science ®Google Scholar
• Laurent A, Mistretta F, Bottigioli D, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine. 2007 Aug 21;25(34):6423–6430. doi: 10.1016/j.vaccine.2007.05.046
   PubMed Web of Science ®Google Scholar
• Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine. 2007 Dec 17;25(52):8833–8842. doi: 10.1016/j.vaccine.2007.10.020
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine. 2008 Dec 2;26(51):6614–6619. doi: 10.1016/j.vaccine.2008.09.078
   PubMed Web of Science ®Google Scholar
• Van Damme P, Arnou R, Kafeja F, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis. 2010 May 26;10(1):134. doi: 10.1186/1471-2334-10-134
   PubMedGoogle Scholar
• Hung IF, Levin Y, To KK, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012 Oct 5;30(45):6427–6435. doi: 10.1016/j.vaccine.2012.08.014
   PubMed Web of Science ®Google Scholar
• Troy SB, Kouiavskaia D, Siik J, et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-Infected adults. J Infect Dis. 2015 Jun 15;211(12):1969–1976. doi: 10.1093/infdis/jiu841
   PubMed Web of Science ®Google Scholar
• Van Damme P, Oosterhuis-Kafeja F, der Wielen M V, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 2009 Jan 14;27(3):454–459. doi: 10.1016/j.vaccine.2008.10.077
   PubMed Web of Science ®Google Scholar
• Della Cioppa G, Nicolay U, Lindert K, et al. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Hum Vaccin Immunother. 2014;10(6):1701–1710. doi: 10.4161/hv.28618
   PubMed Web of Science ®Google Scholar
• Levin Y, Kochba E, Kenney R. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same? Vaccine. 2014 Jul 23;32(34):4249–4252. doi: 10.1016/j.vaccine.2014.03.024
   PubMed Web of Science ®Google Scholar
• Hepatitis B associated with jet gun injection — California. Morbidity Mortality Weekly Rep. 1986;35(23):373–376.
   PubMedGoogle Scholar
• Jackson LA, Austin G, Chen RT, et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine. 2001 Sep 14;19(32):4703–4709. doi: 10.1016/S0264-410X(01)00225-0
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010 Jun 24;362(25):2351–2359. doi: 10.1056/NEJMoa0909383
   PubMed Web of Science ®Google Scholar
• Wang R, Epstein J, Baraceros FM, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10817–10822. doi: 10.1073/pnas.181123498
   PubMed Web of Science ®Google Scholar
• Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011 Oct 26;29(46):8417–8428. doi: 10.1016/j.vaccine.2011.08.001
   PubMed Web of Science ®Google Scholar
• Beckett CG, Tjaden J, Burgess T, et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine. 2011 Jan 29;29(5):960–968. doi: 10.1016/j.vaccine.2010.11.050
   PubMed Web of Science ®Google Scholar
• Bråve A, Ljungberg K, Boberg A, et al. Multigene/Multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther. 2005 Dec;12(6):1197–1205. doi: 10.1016/j.ymthe.2005.06.473
   PubMed Web of Science ®Google Scholar
• Cattamanchi A, Posavad CM, Wald A, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol. 2008 Nov;15(11):1638–1643. doi: 10.1128/CVI.00167-08
   PubMed Web of Science ®Google Scholar
• Epstein JE, Gorak EJ, Charoenvit Y, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther. 2002 Sep 1;13(13):1551–1560. doi: 10.1089/10430340260201644
   PubMed Web of Science ®Google Scholar
• Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One. 2010 Sep 21;5(9):e12873. doi: 10.1371/journal.pone.0012873
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010 May 1;201(9):1344–1352. doi: 10.1086/651611
   PubMed Web of Science ®Google Scholar
• Ault A, Zajac AM, Kong WP, et al. Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine. 2012 Jun 6;30(26):3965–3974. doi: 10.1016/j.vaccine.2012.03.026
   PubMed Web of Science ®Google Scholar
• Estívariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis. 2012 Feb;12(2):128–135. doi: 10.1016/S1473-3099(11)70190-6
   PubMed Web of Science ®Google Scholar
• Gorres JP, Lager KM, Kong WP, et al. DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clin Vaccine Immunol. 2011 Nov;18(11):1987–1995. doi: 10.1128/CVI.05171-11
   PubMedGoogle Scholar
• Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis. 2014 Sep;14(9):830–838. doi: 10.1016/S1473-3099(14)70811-4
   PubMed Web of Science ®Google Scholar
• Swain WE, Heydenburg Fuller D, Wu MS, et al. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B. Dev Biol (Basel). 2000;104:115–119.
   PubMedGoogle Scholar
• Chen D, Zuleger C, Chu Q, et al. Epidermal powder immunization with a recombinant HIV gp120 targets langerhans cells and induces enhanced immune responses. AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):715–722. doi: 10.1089/088922202760072348
   PubMed Web of Science ®Google Scholar
• Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine. 2004 Dec 16;23(5):681–686. doi: 10.1016/j.vaccine.2004.06.041
   PubMed Web of Science ®Google Scholar
• Osorio JE, Zuleger CL, Burger M, et al. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol. 2003 Feb;81(1):52–58. doi: 10.1046/j.1440-1711.2003.01134.x
   PubMed Web of Science ®Google Scholar
• Roberts LK, Barr LJ, Fuller DH, et al. Clinical safety and efficacy of a powdered hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine. 2005 Sep 23;23(40):4867–4878. doi: 10.1016/j.vaccine.2005.05.026
   PubMed Web of Science ®Google Scholar
• Kendall MAF, Quinlan NJ, Thorpe SJ, et al. Measurements of the gas and particle flow within a converging-diverging nozzle for high speed powdered vaccine and drug delivery. Exp Fluids. 2004 Jul 1;37(1):128–136. doi: 10.1007/s00348-004-0792-4
   Web of Science ®Google Scholar
• Guillot AJ, Cordeiro AS, Donnelly RF, et al. Microneedle-based delivery: an overview of Current applications and trends. Pharmaceutics. 2020;12(6):569. doi: 10.3390/pharmaceutics12060569
   PubMed Web of Science ®Google Scholar
• Kirkby M, Hutton ARJ, Donnelly RF. Microneedle mediated transdermal delivery of protein, peptide and antibody based therapeutics: Current status and future considerations. Pharm Res. 2020 Jun 2;37(6):117. doi: 10.1007/s11095-020-02844-6
   PubMed Web of Science ®Google Scholar
• Lee KJ, Jeong SS, Roh DH, et al. A practical guide to the development of microneedle systems – in clinical trials or on the market. Int J Pharm. 2020 Jan 5;573:118778.
   PubMedGoogle Scholar
• Chu LY, Prausnitz MR. Separable arrowhead microneedles. J Control Release. 2011 Feb 10;149(3):242–249. doi: 10.1016/j.jconrel.2010.10.033
   PubMed Web of Science ®Google Scholar
• Courtenay AJ, Rodgers AM, McCrudden MTC, et al. Novel hydrogel-forming microneedle array for intradermal vaccination in Mice using Ovalbumin as a model protein antigen. Mol Pharm. 2019 Jan 7;16(1):118–127. doi: 10.1021/acs.molpharmaceut.8b00895
   PubMedGoogle Scholar
• Fonseca DFS, Vilela C, Silvestre AJD, et al. A compendium of current developments on polysaccharide and protein-based microneedles. Int j biol macromol. 2019 Sep 1;136:704–728.
   PubMed Web of Science ®Google Scholar
• Jeong H-R, Bae J-Y, Park J-H, et al. Preclinical study of influenza bivalent vaccine delivered with a two compartmental microneedle array. J Control Release. 2020 Aug 10;324:280–288.
   PubMed Web of Science ®Google Scholar
• Lee JW, Choi S-O, Felner EI, et al. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small. 2011;7(4):531–539. doi: 10.1002/smll.201001091
   PubMed Web of Science ®Google Scholar
• Park J-H, Choi S-O, Kamath R, et al. Polymer particle-based micromolding to fabricate novel microstructures. Biomed Microdevices. 2007 Apr 1;9(2):223–234. doi: 10.1007/s10544-006-9024-4
   PubMed Web of Science ®Google Scholar
• Prausnitz MR. Microneedles for transdermal drug delivery.Adv Drug Delivery Rev. 2004 Mar 27;56(5):581–587. doi: 10.1016/j.addr.2003.10.023
   PubMed Web of Science ®Google Scholar
• Trautmann A, Roth G-L, Nujiqi B, et al. Towards a versatile point-of-care system combining femtosecond laser generated microfluidic channels and direct laser written microneedle arrays. Microsyst Nanoeng. 2019 Feb 25;5(1):6. doi: 10.1038/s41378-019-0046-5
   PubMedGoogle Scholar
• van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release. 2012 Jul 20;161(2):645–655. doi: 10.1016/j.jconrel.2012.01.042
   PubMed Web of Science ®Google Scholar
• Xiang Z, Wang H, Pant A, et al. Development of vertical SU-8 microtubes integrated with dissolvable tips for transdermal drug delivery. Biomicrofluidics. 2013;7(2):026502. doi: 10.1063/1.4798471
   PubMed Web of Science ®Google Scholar
• Prüss-Üstün A, Rapiti E, Hutin YJF. Sharps injuries: global burden of disease from sharps injuries to health-care workers/Annette prüss-Üstun, Elisabetta Rapiti, Yvan Hutin. EBD Series. 2003;2003:26–28.
   Google Scholar
• Kolluru C, Gomaa Y, Prausnitz MR. Development of a thermostable microneedle patch for polio vaccination. Drug Deliv Transl Res. 2019;9(1):192–203. doi: 10.1007/s13346-018-00608-9
   PubMed Web of Science ®Google Scholar
• McMillan CLD, Choo JJY, Idris A, et al. Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine. Sci Adv. 2021;7(44):eabj8065. doi: 10.1126/sciadv.abj8065
   PubMed Web of Science ®Google Scholar
• Mistilis MJ, Bommarius AS, Prausnitz MR. Development of a thermostable microneedle patch for influenza vaccination.J Pharm Sci. 2015 Feb 1;104(2):740–749. doi: 10.1002/jps.24283
   PubMed Web of Science ®Google Scholar
• Wan Y, Gupta V, Bird C, et al. Formulation development and improved stability of a combination measles and rubella live-viral vaccine dried for use in the Nanopatch(TM) microneedle delivery system. Hum Vaccin Immunother. 2021 May 6;17(8):16. doi: 10.1080/21645515.2021.1887692
   Web of Science ®Google Scholar
• Wan Y, Hickey JM, Bird C, et al. Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the Nanopatch microprojection array. J Pharm Sci. 2018 Jun;107(6):1540–1551. doi: 10.1016/j.xphs.2018.01.027
   PubMed Web of Science ®Google Scholar
• Privor-Dumm L, Excler JL, Gilbert S, et al. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Glob Health. 2023 Jun;8(6):e011881. doi: 10.1136/bmjgh-2023-011881
   PubMed Web of Science ®Google Scholar
• Excler JL, Privor-Dumm L, Kim JH. Supply and delivery of vaccines for global health. Curr Opin Immunol. 2021 Aug;71:13–20. doi: 10.1016/j.coi.2021.03.009
   PubMed Web of Science ®Google Scholar
• Ding Z, Verbaan FJ, Bivas-Benita M, et al. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control Release. 2009 MAY 21;136(1):71–78. doi: 10.1016/j.jconrel.2009.01.025
   PubMed Web of Science ®Google Scholar
• Guo L, Qiu YQ, Chen JM, et al. Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays. Biomed Microdevices. 2013 Dec;15(6):1077–1085. doi: 10.1007/s10544-013-9799-z
   PubMed Web of Science ®Google Scholar
• Dean CH, Alarcon JB, Waterston AM, et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax (TM)-JE) in Non-human primates. Hum Vaccin. 2005 May;1(3):106–111. doi: 10.4161/hv.1.3.1797
   PubMed Web of Science ®Google Scholar
• Kim YC, Yoo DG, Compans RW, et al. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release. 2013 DEC 10;172(2):579–588. doi: 10.1016/j.jconrel.2013.04.016
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Yoo DG, et al. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine. 2009 Nov 16;27(49):6932–6938. doi: 10.1016/j.vaccine.2009.08.108
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Compans RW, et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2010 Mar 3;142(2):187–195. doi: 10.1016/j.jconrel.2009.10.013
   PubMed Web of Science ®Google Scholar
• Jeong HR, Park S, Park JH, et al. Preparation of H1N1 microneedles by a low-temperature process without a stabilizer. Eur J Pharm Biopharm. 2019 Oct;143:1–7.
   PubMed Web of Science ®Google Scholar
• Depelsenaire ACI, Meliga SC, McNeilly CL, et al. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. J Invest Dermatol. 2014 Sep;134(9):2361–2370. doi: 10.1038/jid.2014.174
   PubMed Web of Science ®Google Scholar
• Fernando GJ, Chen X, Prow TW, et al. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One. 2010 Apr 21;5(4):e10266. doi: 10.1371/journal.pone.0010266
   PubMed Web of Science ®Google Scholar
• Fernando GJP, Hickling J, Jayashi Flores CM, et al. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine. 2018 Jun 18;36(26):3779–3788. doi: 10.1016/j.vaccine.2018.05.053
   PubMed Web of Science ®Google Scholar
• Forster AH, Witham K, Depelsenaire ACI, et al. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: results from a randomized, controlled phase I clinical trial. PLOS Med. 2020;17(3):e1003024. doi: 10.1371/journal.pmed.1003024
   PubMed Web of Science ®Google Scholar
• Kim MC, Lee JW, Choi HJ, et al. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. J Control Release. 2015 Jul 28;210:208–216.
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Compans RW, et al. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS Pharm Sci Tech. 2010 Sep;11(3):1193–1201. doi: 10.1208/s12249-010-9471-3
   PubMed Web of Science ®Google Scholar
• Kim YC, Song JM, Lipatov AS, et al. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm. 2012 Jun;81(2):239–247. doi: 10.1016/j.ejpb.2012.03.010
   PubMed Web of Science ®Google Scholar
• Kommareddy S, Baudner BC, Bonificio A, et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine. 2013 Jul 25;31(34):3435–3441. doi: 10.1016/j.vaccine.2013.01.050
   PubMed Web of Science ®Google Scholar
• Wire B Vaxxas Announces Initiation of Phase I clinical study of first needle-free COVID-19 vaccine (HexaPro) delivered using high-density microarray patch (HD-MAP): business Wire; 2022 [cited 2023 Jun 28]. Available from: https://www.businesswire.com/news/home/20221108005505/en/Vaxxas-Announces-Initiation-of-Phase-I-Clinical-Study-of-First-Needle-Free-COVID-19-Vaccine-HexaPro-Delivered-Using-High-Density-Microarray-Patch-HD-MAP
   Google Scholar
• Wire B Vaxxas Announces Interim results from Phase I clinical study of first needle-free COVID-19 vaccine delivered using Proprietary high-density microarray patch (HD-MAP) businesswire.com: business Wire; 2023 updated 5 June 2023 [cited 2023 Jun 28]. Available from: https://www.businesswire.com/news/home/20230605005248/en/Vaxxas-Announces-Interim-Results-from-Phase-I-Clinical-Study-of-First-Needle-Free-COVID-19-Vaccine-Delivered-Using-Proprietary-High-Density-Microarray-Patch-HD-MAP
   Google Scholar
• McMillan CLD, Amarilla AA, Modhiran N, et al. Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern. Vaccine. 2022 Aug 12;40(34):4929–4932. doi: 10.1016/j.vaccine.2022.07.013
   PubMed Web of Science ®Google Scholar
• McMillan CLD, Azuar A, Choo JJY, et al. Dermal delivery of a SARS-CoV-2 subunit vaccine induces immunogenicity against variants of concern. Vaccines. 2022;10(4):578. doi: 10.3390/vaccines10040578
   Web of Science ®Google Scholar
• Choo JJY, McMillan CLD, Fernando GJP, et al. Developing a stabilizing formulation of a live chimeric dengue virus vaccine dry coated on a high-density microarray patch. Vaccines. 2021;9(11):1301. doi: 10.3390/vaccines9111301
   Web of Science ®Google Scholar
• Choo JJY, Vet LJ, McMillan CLD, et al. A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice. NPJ Vaccines. 2021 May 7;6(1):66. doi: 10.1038/s41541-021-00328-1
   PubMed Web of Science ®Google Scholar
• Muller DA, Depelsenaire ACI, Shannon AE, et al. Efficient delivery of dengue virus subunit vaccines to the skin by Microprojection Arrays. Vaccines. 2019 Nov 20;7(4):189–202. doi: 10.3390/vaccines7040189
   Web of Science ®Google Scholar
• Corbett HJ, Fernando GJ, Chen X, et al. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One. 2010 Oct 18;5(10):e13460. doi: 10.1371/journal.pone.0013460
   PubMed Web of Science ®Google Scholar
• Kines RC, Zarnitsyn V, Johnson TR, et al. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles. PLoS One. 2015 Mar 18;10(3): doi: 10.1371/journal.pone.0120797
   PubMed Web of Science ®Google Scholar
• Edens C, Collins ML, Ayers J, et al. Measles vaccination using a microneedle patch. Vaccine. 2013 Jul 25;31(34):3403–3409. doi: 10.1016/j.vaccine.2012.09.062
   PubMed Web of Science ®Google Scholar
• Edens C, Collins ML, Goodson JL, et al. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. 2015;33(37):4712–4718. doi: 10.1016/j.vaccine.2015.02.074
   PubMed Web of Science ®Google Scholar
• Gill HS, Soderholm J, Prausnitz MR, et al. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther. 2010 Jun;17(6):811–814. doi: 10.1038/gt.2010.22
   PubMed Web of Science ®Google Scholar
• Kask AS, Chen X, Marshak JO, et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine. 2010 Nov 3;28(47):7483–7491. doi: 10.1016/j.vaccine.2010.09.014
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye L, Lin F, et al. Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge. Sci Rep. 2018 Jul 25;8. doi: 10.1038/s41598-018-29135-w
   Web of Science ®Google Scholar
• Moon S, Wang YH, Edens C, et al. Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine. 2013 JUL 25;31(34):3396–3402.
   PubMed Web of Science ®Google Scholar
• Muller DA, Fernando GJP, Owens NS, et al. High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. Sci Rep. 2017 Oct 3;7(1):12644. doi: 10.1038/s41598-017-13011-0
   PubMedGoogle Scholar
• Muller DA, Pearson FE, Fernando GJ, et al. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Sci Rep. 2016 Feb 25;6(1):22094. doi: 10.1038/srep22094
   PubMedGoogle Scholar
• van der Maaden K, Sekerdag E, Schipper P, et al. Layer-by-layer assembly of inactivated poliovirus and N-Trimethyl chitosan on pH-Sensitive microneedles for dermal vaccination. Langmuir. 2015 Aug 11;31(31):8654–8660. doi: 10.1021/acs.langmuir.5b01262
   PubMed Web of Science ®Google Scholar
• Park S, Lee Y, Kwon YM, et al. Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid a enhances the protective efficacy and diminishes inflammatory disease after challenge. PLoS One. 2018 Oct 26;13(10): doi: 10.1371/journal.pone.0205071
   Web of Science ®Google Scholar
• Prow TW, Chen X, Prow NA, et al. Nanopatch-targeted skin vaccination against West Nile virus and Chikungunya virus in mice. Small. 2010 Aug 16;6(16):1776–1784. doi: 10.1002/smll.201000331
   PubMed Web of Science ®Google Scholar
• Zhu WD, Pewin W, Wang C, et al. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines. J Control Release. 2017 Sep 10;261:1–9.
   PubMed Web of Science ®Google Scholar
• Bonificio A, Ghartey-Tagoe E, Gallorini S, et al. Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs. Vaccine. 2015 Jun 9;33(25):2930–2938. doi: 10.1016/j.vaccine.2015.04.059
   PubMed Web of Science ®Google Scholar
• Kommareddy S, Baudner BC, Oh S, et al. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci. 2012 Mar;101(3):1021–1027. doi: 10.1002/jps.23019
   PubMed Web of Science ®Google Scholar
• Nakatsukasa A, Kuruma K, Okamatsu M, et al. Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice. Vaccine. 2017 May 15;35(21):2855–2861. doi: 10.1016/j.vaccine.2017.04.009
   PubMed Web of Science ®Google Scholar
• Raphael AP, Prow TW, Crichton ML, et al. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small. 2010 Aug 16;6(16):1785–1793. doi: 10.1002/smll.201000326
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination [10.1038/nm.2182]. Nat Med. 2010 08//print;16(8):915–920. doi: 10.1038/nm.2182
   PubMed Web of Science ®Google Scholar
• Vassilieva EV, Kalluri H, McAllister D, et al. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res. 2015 Aug;5(4):360–371. doi: 10.1007/s13346-015-0228-0
   PubMed Web of Science ®Google Scholar
• Vrdoljak A, Allen EA, Ferrara F, et al. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods. J Control Release. 2016 Mar 10;225:192–204.
   PubMed Web of Science ®Google Scholar
• Wang J, Li B, Wu MX. Effective and lesion-free cutaneous influenza vaccination. Proc Natl Acad Sci. 2015 APR 21;112(16):5005–5010.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Paine M, Mosley R, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017 Aug 12;390(10095):649–658. doi: 10.1016/S0140-6736(17)30575-5
   PubMed Web of Science ®Google Scholar
• Hirobe S, Azukizawa H, Hanafusa T, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 2015 JUL;57:50–58.
   PubMed Web of Science ®Google Scholar
• Arya JM, Dewitt K, Scott-Garrard M, et al. Rabies vaccination in dogs using a dissolving microneedle patch. J Control Release. 2016 Oct 10;239:19–26.
   PubMed Web of Science ®Google Scholar
• Beaver JT, Mills LK, Swieboda D, et al. Cutaneous vaccination ameliorates Zika virus-induced neuro-ocular pathology via reduction of anti-ganglioside antibodies. Hum Vaccin Immunother. 2020 Sep 1;16(9):2072–2091. doi: 10.1080/21645515.2020.1775460
   PubMed Web of Science ®Google Scholar
• Kim E, Erdos G, Huang S, et al. Preventative vaccines for Zika virus outbreak: preliminary Evaluation. EBioMedicine. 2016;13:315–320. doi: 10.1016/j.ebiom.2016.09.028
   PubMed Web of Science ®Google Scholar
• Christiansen D, Earnest-Silveira L, Grubor-Bauk B, et al. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep. 2019 Jun 25;9. doi: 10.1038/s41598-019-45461-z
   Web of Science ®Google Scholar
• Donadei A, Kraan H, Ophorst O, et al. Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies. J Control Release. 2019 Oct;311:96–103.
   PubMed Web of Science ®Google Scholar
• Edens C, Dybdahl-Sissoko NC, Weldon WC, et al. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine. 2015 Sep 8;33(37):4683–4690. doi: 10.1016/j.vaccine.2015.01.089
   PubMed Web of Science ®Google Scholar
• Joyce JC, Carroll TD, Collins ML, et al. A microneedle patch for measles and rubella vaccination is immunogenic and protective in infant rhesus macaques. J Infect Dis. 2018 Jul 1;218(1):124–132. doi: 10.1093/infdis/jiy139
   PubMed Web of Science ®Google Scholar
• Kim E, Erdos G, Huang SH, et al. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine. 2020 May;55. doi: 10.1016/j.ebiom.2020.102743
   PubMed Web of Science ®Google Scholar
• Patil S, Vijayanand S, Joshi D, et al. Subunit microparticulate vaccine delivery using microneedles trigger significant SARS-spike-specific humoral and cellular responses in a preclinical murine model. Int J Pharm. 2023 Feb 5;632:122583. doi: 10.1016/j.ijpharm.2023.122583
   PubMedGoogle Scholar
• Pattani A, McKay PF, Garland MJ, et al. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J Control Release. 2012 Sep 28;162(3):529–537. doi: 10.1016/j.jconrel.2012.07.039
   PubMed Web of Science ®Google Scholar
• Zaric M, Becker PD, Hervouet C, et al. Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8(+) effector recruitment to mucosal tissues. Nat Commun. 2019 May 17;10(1): doi: 10.1038/s41467-019-09969-2
   PubMedGoogle Scholar
• Boopathy AV, Mandal A, Kulp DW, et al. Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination. Proc Natl Acad Sci. 2019;116(33):16473–16478. doi: 10.1073/pnas.1902179116
   PubMed Web of Science ®Google Scholar
• Zaric M, Becker PD, Hervouet C, et al. Long-lived tissue resident HIV-1 specific memory CD8(+) T cells are generated by skin immunization with live virus vectored microneedle arrays. J Control Release. 2017 Dec 28;268:166–175.
   PubMed Web of Science ®Google Scholar
• Perez Cuevas MB, Kodani M, Choi Y, et al. Hepatitis B vaccination using a dissolvable microneedle patch is immunogenic in mice and rhesus macaques. Bioeng Transl Med. 2018;3(3):186–196. doi: 10.1002/btm2.10098
   PubMed Web of Science ®Google Scholar
• Poirier D, Renaud F, Dewar V, et al. Hepatitis B surface antigen incorporated in dissolvable microneedle array patch is antigenic and thermostable. Biomaterials. 2017 Nov;145:256–265.
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee GS, Li S, et al. Hepatitis B vaccine delivered by microneedle patch: immunogenicity in mice and rhesus macaques. Vaccine. 2023 Jun 1;41(24):3663–3672. doi: 10.1016/j.vaccine.2023.05.005
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhu J, Zheng C, et al. Dissolving microneedle arrays as a hepatitis B vaccine delivery system adjuvanted by APC-Targeted poly (lactic-co-glycolic acid) (PLGA) nanoparticles. AAPS Pharm Sci Tech. 2023 Jan 25;24(1):42. doi: 10.1208/s12249-022-02473-9
   PubMed Web of Science ®Google Scholar
• Qiu YQ, Guo L, Zhang SH, et al. DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Deliv. 2016 Sep;23(7):2391–2398. doi: 10.3109/10717544.2014.992497
   PubMed Web of Science ®Google Scholar
• Turvey ME, Uppu DSSM, Mohamed Sharif AR, et al. Microneedle-based intradermal delivery of stabilized dengue virus. Bioeng Transl Med. 2019;4(2):e10127. doi: 10.1002/btm2.10127
   PubMed Web of Science ®Google Scholar
• Yang HW, Ye L, Guo XD, et al. Ebola vaccination using a DNA vaccine coated on PLGA-PLL/gamma PGA nanoparticles administered using a microneedle patch. Adv Healthc Mater. 2017 Jan;6(1). doi: 10.1002/adhm.201600750
   Web of Science ®Google Scholar
• Romanyuk A, Wang R, Marin A, et al. Skin vaccination with Ebola virus glycoprotein using a polyphosphazene-based microneedle patch protects Mice against lethal challenge. J Funct Biomater. 2022 Dec 27;14(1):16. doi: 10.3390/jfb14010016
   PubMed Web of Science ®Google Scholar
• Biomedical M Micron Biomedical Announces positive measles and rubella vaccination results from first clinical trial of microarray injection-free vaccine delivery in children: Micron Biomedical; 2023 updated 17 May 2023. cited 2023 Jun 29. Available from: https://www.micronbiomedical.com/positive-measles-rubella
   Google Scholar
• Adigweme I, Akpalu E, Yisa M, et al. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in the Gambia [measles and rubella vaccine microneedle patch Phase 1/2 age De-escalation trial]. Trials. 2022 Sep 14;23(1):775. doi: 10.1186/s13063-022-06493-5
   PubMed Web of Science ®Google Scholar
• Iwata H, Kakita K, Imafuku K, et al. Safety and dose-sparing effect of Japanese encephalitis vaccine administered by microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial. Lancet Microbe. 2022 Feb 1;3(2):e96–e104. doi: 10.1016/S2666-5247(21)00269-X
   PubMedGoogle Scholar
• Ogai N, Nonaka I, Toda Y, et al. Enhanced immunity in intradermal vaccination by novel hollow microneedles. Skin Res Technol. 2018 Nov;24(4):630–635. doi: 10.1111/srt.12576
   PubMed Web of Science ®Google Scholar
• Schipper P, van der Maaden K, Romeijn S, et al. Repeated fractional intradermal dosing of an inactivated polio vaccine by a single hollow microneedle leads to superior immune responses. J Control Release. 2016 Nov 28;242:141–147.
   PubMed Web of Science ®Google Scholar
• van der Maaden K, Trietsch SJ, Kraan H, et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in Rats. Pharm Res. 2014 Jul;31(7):1846–1854. doi: 10.1007/s11095-013-1288-9
   PubMed Web of Science ®Google Scholar
• Prins MLM, Prins C, de Vries JJC, et al. Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers. Virus Res. 2023 Sep;334:199175.
   PubMed Web of Science ®Google Scholar
• Korkmaz E, Balmert SC, Carey CD, et al. Emerging skin-targeted drug delivery strategies to engineer immunity: a focus on infectious diseases. Expert Opin Drug Deliv. 2021 Feb 1;18(2):151–167. doi: 10.1080/17425247.2021.1823964
   PubMed Web of Science ®Google Scholar
• Korkmaz E, Balmert SC, Sumpter TL, et al. Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Delivery Rev. 2021 Apr 1;171:164–186.
   PubMed Web of Science ®Google Scholar
• van der Straeten A, Sarmadi M, Daristotle JL, et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat Biotechnol. 2023 Apr 24. doi: 10.1038/s41587-023-01774-z
   Web of Science ®Google Scholar
• Bae WG, Ko H, So JY, et al. Snake fang-inspired stamping patch for transdermal delivery of liquid formulations. Sci Transl Med. 2019 Jul 31;11(503): doi: 10.1126/scitranslmed.aaw3329
   Web of Science ®Google Scholar
• Balmert SC, Carey CD, Falo GD, et al. Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination. J Control Release. 2020 Jan 10;317:336–346.
   PubMed Web of Science ®Google Scholar
• Bediz B, Korkmaz E, Khilwani R, et al. Dissolvable microneedle arrays for intradermal delivery of biologics: fabrication and application. Pharm Res. 2014 Jan;31(1):117–135. doi: 10.1007/s11095-013-1137-x
   PubMed Web of Science ®Google Scholar
• Crichton ML, Muller DA, Depelsenaire ACI, et al. The changing shape of vaccination: improving immune responses through geometrical variations of a microdevice for immunization. Sci Rep. 2016 Jun 2;6(1):27217. doi: 10.1038/srep27217
   PubMedGoogle Scholar
• Johnson AR, Caudill CL, Tumbleston JR, et al. Single-step fabrication of computationally designed microneedles by continuous liquid interface production. PLoS One. 2016 Sep 8;11(9): doi: 10.1371/journal.pone.0162518
   Web of Science ®Google Scholar
• Kim MJ, Park SC, Rizal B, et al. Fabrication of Circular Obelisk-type Multilayer microneedles using micro-milling and spray deposition. Front Bioeng Biotechnol. 2018 May 11;6. doi: 10.3389/fbioe.2018.00054
   Web of Science ®Google Scholar
• Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Delivery Rev. 2012 Nov;64(14):1547–1568. doi: 10.1016/j.addr.2012.04.005
   PubMed Web of Science ®Google Scholar
• Gupta J, Gupta R, Vanshita R. Microneedle technology: an insight into recent advancements and future trends in drug and vaccine delivery.Assay Drug Dev Technol. 2020 Mar 1;19(2):97–114. doi: 10.1089/adt.2020.1022
   PubMed Web of Science ®Google Scholar
• Tariq N, Ashraf MW, Tayyaba S. A review on solid microneedles for Biomedical applications.J Pharm Innov. 2022 Dec 1;17(4):1464–1483. doi: 10.1007/s12247-021-09586-x
   Web of Science ®Google Scholar
• Dean CH, Alarcon JB, Waterston AM, et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccines against Japanese encephalitis (ChimeriVaxTM-JE) in Non-human primates. Hum Vaccines. 2005 May 1;1(3):106–111. doi: 10.4161/hv.1.3.1797
   PubMedGoogle Scholar
• Gill HS, Andrews SN, Sakthivel SK, et al. Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci. 2009 Sep 10;38(2):95–103. doi: 10.1016/j.ejps.2009.06.004
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Alarcon JB, Brittingham JM, et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med. 2002 Apr 1;8(4):415–419. doi: 10.1038/nm0402-415
   PubMed Web of Science ®Google Scholar
• Pearton M, Kang S-M, Song J-M, et al. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine. 2010 Aug 23;28(37):6104–6113. doi: 10.1016/j.vaccine.2010.05.055
   PubMed Web of Science ®Google Scholar
• Henry S, McAllister DV, Allen MG, et al. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998 Aug;87(8):922–925.
   PubMed Web of Science ®Google Scholar
• Iliescu F, Dumitrescu-Ionescu D, Petrescu M, et al. A review on transdermal drug delivery using microneedles: Current research and perspective. Ann Acad Rom Sci. 2014 Jul 01;7:7–34.
   Google Scholar
• DeMuth PC, Li AV, Abbink P, et al. Vaccine delivery with microneedle skin patches in nonhuman primates. Nat Biotechnol. 2013 Dec;31(12):1082–1085. doi: 10.1038/nbt.2759
   PubMed Web of Science ®Google Scholar
• Fernando GJ, Chen X, Primiero CA, et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release. 2012 Apr 30;159(2):215–221. doi: 10.1016/j.jconrel.2012.01.030
   PubMed Web of Science ®Google Scholar
• Muller DA, Henricson J, Baker SB, et al. Innate local response and tissue recovery following application of high density microarray patches to human skin. Sci Rep. 2020 Oct 28;10(1):18468. doi: 10.1038/s41598-020-75169-4
   PubMed Web of Science ®Google Scholar
• Ng HI, Fernando GJ, Kendall MA. Induction of potent CD8(+) T cell responses through the delivery of subunit protein vaccines to skin antigen-presenting cells using densely packed microprojection arrays. J Control Release. 2012 Sep 28;162(3):477–484. doi: 10.1016/j.jconrel.2012.07.024
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Compans RW, et al. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release. 2010 Nov 1;147(3):326–332. doi: 10.1016/j.jconrel.2010.07.125
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Song JM, et al. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol. 2013 Sep;20(9):1433–1439. doi: 10.1128/CVI.00251-13
   PubMed Web of Science ®Google Scholar
• Weldon WC, Martin MP, Zarnitsyn V, et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol. 2011 Apr;18(4):647–654. doi: 10.1128/CVI.00435-10
   PubMed Web of Science ®Google Scholar
• Zhu QY, Zarnitsyn VG, Ye L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci. 2009 May 12;106(19):7968–7973. doi: 10.1073/pnas.0812652106
   PubMed Web of Science ®Google Scholar
• Pearson FE, Muller DA, Roalfe L, et al. Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. Vaccine. 2015 Nov 27;33(48):6675–6683. doi: 10.1016/j.vaccine.2015.10.081
   PubMed Web of Science ®Google Scholar
• Henricson J, Muller DA, Baker SB, et al. Micropuncture closure following high density microarray patch application in healthy subjects. Skin Res Technol. 2022;28(2):305–310. doi: 10.1111/srt.13131
   PubMed Web of Science ®Google Scholar
• Al-Japairai KAS, Mahmood S, Almurisi SH, et al. Current trends in polymer microneedle for transdermal drug delivery. Int J Pharm. 2020 Sep;25:587.
   Google Scholar
• Larraneta E, Lutton REM, Woolfson AD, et al. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development. Mater Sci Eng R Rep. 2016 Jun;104:1–32.
   Web of Science ®Google Scholar
• Boopathy AV, Mandal A, Kulp DW, et al. Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination. Proc Nat Acad Sci. 2019;116(33):16473–16478. doi: 10.1073/pnas.1902179116
   PubMed Web of Science ®Google Scholar
• Hirobe S, Azukizawa H, Matsuo K, et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res. 2013 Oct 1;30(10):2664–2674. doi: 10.1007/s11095-013-1092-6
   PubMed Web of Science ®Google Scholar
• Moore LE, Vucen S, Moore AC. Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication. Eur J Pharm Biopharm. 2022 Apr 1;173:54–72. doi: 10.1016/j.ejpb.2022.02.013
   PubMed Web of Science ®Google Scholar
• Vassilieva EV, Li S, Korniychuk H, et al. cGamp/saponin adjuvant combination improves protective response to influenza vaccination by microneedle patch in an aged mouse model [original research]. Front Immunol. 2021 Feb 2;11:11.
   PubMed Web of Science ®Google Scholar
• Chen MC, Lai KY, Ling MH, et al. Enhancing immunogenicity of antigens through sustained intradermal delivery using chitosan microneedles with a patch-dissolvable design. Acta Biomaterialia. 2018 Jan;65:66–75.
   PubMed Web of Science ®Google Scholar
• Zaric M, Lyubomska O, Poux C, et al. Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine langerhans cells. J Invest Dermatol. 2015 Feb;135(2):425–434. doi: 10.1038/jid.2014.415
   PubMed Web of Science ®Google Scholar
• Paredes AJ, McKenna PE, Ramoller IK, et al. Microarray patches: poking a hole in the challenges faced when delivering poorly soluble drugs. Adv Funct Mater. 2021 Jan;31(1). doi: 10.1002/adfm.202005792
   Web of Science ®Google Scholar
• Vinayakumar KB, Kulkarni PG, Nayak MM, et al. A hollow stainless steel microneedle array to deliver insulin to a diabetic rat. J Micromech Microeng. 2016 Jun;26(6):065013. doi: 10.1088/0960-1317/26/6/065013
   Web of Science ®Google Scholar
• Cárcamo-Martínez Á, Mallon B, Domínguez-Robles J, et al. Hollow microneedles: a perspective in biomedical applications. Int J Pharm. 2021 Apr 15;599:120455.
   PubMedGoogle Scholar
• Du G, Hathout RM, Nasr M, et al. Intradermal vaccination with hollow microneedles: a comparative study of various protein antigen and adjuvant encapsulated nanoparticles. J Control Release. 2017 Nov 28;266:109–118.
   PubMed Web of Science ®Google Scholar
• Niu L, Chu LY, Burton SA, et al. Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response. J Control Release. 2019 Jan 28;294:268–278.
   PubMed Web of Science ®Google Scholar
• Du G, Woythe L, van der Maaden K, et al. Coated and hollow microneedle-mediated intradermal immunization in Mice with diphtheria toxoid loaded mesoporous silica nanoparticles. Pharm Res. 2018 Aug 13;35(10):189. doi: 10.1007/s11095-018-2476-4
   PubMed Web of Science ®Google Scholar
• Norman JJ, Brown MR, Raviele NA, et al. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2013;14(6):459–465. doi: 10.1111/pedi.12031
   PubMed Web of Science ®Google Scholar
• Norman JJ, Choi S-O, Tong NT, et al. Hollow microneedles for intradermal injection fabricated by sacrificial micromolding and selective electrodeposition. Biomed Microdevices. 2013 Apr 1;15(2):203–210. doi: 10.1007/s10544-012-9717-9
   PubMed Web of Science ®Google Scholar
• Al-Kasasbeh R, Brady AJ, Courtenay AJ, et al. Evaluation of the clinical impact of repeat application of hydrogel-forming microneedle array patches. Drug Deliv Transl Res. 2020 Jun;10(3):690–705. doi: 10.1007/s13346-020-00727-2
   PubMed Web of Science ®Google Scholar
• Donnelly RF, Singh TRR, Garland MJ, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012 Dec 5;22(23):4879–4890. doi: 10.1002/adfm.201200864
   PubMed Web of Science ®Google Scholar
• Turner JG, White LR, Estrela P, et al. Hydrogel-forming microneedles: Current advancements and future trends. Macromol biosci. 2021;21(2):2000307. doi: 10.1002/mabi.202000307
   Web of Science ®Google Scholar
• Ingrole RSJ, Gill HS. Microneedle coating methods: a review with a perspective. J Pharmacol Exp Ther. 2019 Sep;370(3):555–569. doi: 10.1124/jpet.119.258707
   PubMed Web of Science ®Google Scholar
• Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007 Feb 12;117(2):227–237. doi: 10.1016/j.jconrel.2006.10.017
   PubMed Web of Science ®Google Scholar
• Chen X, Corbett HJ, Yukiko SR, et al. Site-Selectively coated, densely-packed microprojection array patches for targeted delivery of vaccines to skin. Adv Funct Mater. 2011;21(3):464–473. doi: 10.1002/adfm.201000966
   Web of Science ®Google Scholar
• Chen X, Fernando GJP, Crichton ML, et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release. 2011 6/30;152(3):349–355. doi: 10.1016/j.jconrel.2011.02.026
   PubMed Web of Science ®Google Scholar
• Vrdoljak A, McGrath MG, Carey JB, et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release. 2012 Apr 10;159(1):34–42. doi: 10.1016/j.jconrel.2011.12.026
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Goodson JL, Rota PA, et al. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination. Curr Opin Virol. 2020 Apr;41:68–76.
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Vunnava A, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol. 2010 Aug;84(15):7760–7769. doi: 10.1128/JVI.01849-09
   PubMed Web of Science ®Google Scholar
• Caudill C, Perry JL, Iliadis K, et al. Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity. Proc Natl Acad Sci. 2021;118(39):e2102595118. doi: 10.1073/pnas.2102595118
   PubMed Web of Science ®Google Scholar
• Forster A, Junger M. Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective.Hum Vaccin Immunother. 2022 Nov 30;18(4):2050123. doi: 10.1080/21645515.2022.2050123
   PubMed Web of Science ®Google Scholar
• Davies C, Taba M, Deng L, et al. Usability, acceptability, and feasibility of a high-density microarray patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings. Hum Vaccin Immunother. 2022 Nov 30;18(4):2018863. doi: 10.1080/21645515.2021.2018863
   PubMed Web of Science ®Google Scholar
• MfIa S. Propelling Australian electric planes minister.Industry.gov.au: Minister for industry and science; 2023 updated 19 January 2023 cited 2023 Jun 28. Available from: https://www.minister.industry.gov.au/ministers/husic/media-releases/propelling-australian-electric-planes
   Google Scholar
• Government A CRC projects selection round outcomes business.Gov.au: Australian Government; 2023 updated 20 February 2023 [cited 2023 Jun 28]. Available from: https://business.gov.au/grants-and-programs/cooperative-research-centres-projects-crcp-grants/crc-projects-selection-round-outcomes
   Google Scholar
• Leone M, Monkare J, Bouwstra J, et al. Dissolving microneedle patches for dermal vaccination. Pharm Res. 2017 Nov;34(11):2223–2240. doi: 10.1007/s11095-017-2223-2
   PubMed Web of Science ®Google Scholar
• DeMuth PC, Min Y, Irvine DJ, et al. Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization. Adv Healthc Mater. 2014;3(1):47–58. doi: 10.1002/adhm.201300139
   PubMed Web of Science ®Google Scholar
• Kang G, Kim M, Yang H, et al. Latch applicator for efficient delivery of dissolving microneedles based on Rapid Release of Elastic strain Energy by thumb force. Adv Funct Mater. 2023;33(11):2210805. doi: 10.1002/adfm.202210805
   Web of Science ®Google Scholar
• Paik S-J, Byun S, Lim J-M, et al. In-plane single-crystal-silicon microneedles for minimally invasive microfluid systems. Sens Actuators A. 2004 Sep 1];114(2):276–284. doi: 10.1016/j.sna.2003.12.029
   Google Scholar
• Cui Q, Liu C, Zha XF. Study on a piezoelectric micropump for the controlled drug delivery system.Microfluid Nanofluidics. [2007 Aug 1;3(4):377–390. doi: 10.1007/s10404-006-0137-0
   Web of Science ®Google Scholar
• Tuan-Mahmood T-M, McCrudden MTC, Torrisi BM, et al. Microneedles for intradermal and transdermal drug delivery. Eur J Pharm Sci. 2013;50(5):623–637. doi: 10.1016/j.ejps.2013.05.005
   PubMed Web of Science ®Google Scholar
• Pamornpathomkul B, Niyomtham N, Yingyongnarongkul BE, et al. Cationic niosomes for enhanced skin immunization of plasmid DNA-Encoding ovalbumin via hollow microneedles. AAPS Pharm Sci Tech. 2018 Jan;19(1):481–488. doi: 10.1208/s12249-017-0855-5
   PubMed Web of Science ®Google Scholar
• Samant PP, Prausnitz MR. Mechanisms of sampling interstitial fluid from skin using a microneedle patch. Proc Natl Acad Sci U S A. 2018 May 1;115(18):4583–4588. doi: 10.1073/pnas.1716772115
   PubMed Web of Science ®Google Scholar
• Romanyuk AV, Zvezdin VN, Samant P, et al. Collection of analytes from microneedle patches. Anal Chem. 2014 Nov 4;86(21):10520–10523. doi: 10.1021/ac503823p
   PubMed Web of Science ®Google Scholar
• Chang H, Zheng M, Yu X, et al. A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic analysis. Adv Mater. 2017;29(37):1702243. doi: 10.1002/adma.201702243
   Web of Science ®Google Scholar
• Caffarel-Salvador E, Brady AJ, Eltayib E, et al. Hydrogel-forming microneedle arrays allow detection of drugs and glucose in vivo: potential for use in Diagnosis and Therapeutic drug Monitoring. PLoS One. 2015;10(12):e0145644. doi: 10.1371/journal.pone.0145644
   PubMed Web of Science ®Google Scholar
• Kearney MC, Caffarel-Salvador E, Fallows SJ, et al. Microneedle-mediated delivery of donepezil: potential for improved treatment options in Alzheimer’s disease. Eur J Pharm Biopharm. 2016 Jun;103:43–50.
   PubMed Web of Science ®Google Scholar
• Courtenay AJ, McAlister E, McCrudden MTC, et al. Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery. J Control Release. 2020 Jun 10;322:177–186. doi: 10.1016/j.jconrel.2020.03.026
   PubMed Web of Science ®Google Scholar
• Shi Y, Truong VX, Kulkarni K, et al. Light-triggered release of ciprofloxacin from an in situ forming click hydrogel for antibacterial wound dressings. J Mater Chem B. 2015 Dec 7;3(45):8771–8774. doi: 10.1039/C5TB01820J
   PubMed Web of Science ®Google Scholar
• Courtenay AJ, McCrudden MTC, McAvoy KJ, et al. Microneedle-mediated transdermal delivery of Bevacizumab. Mol Pharm. [2018 Aug 6];15(8):3545–3556. doi: 10.1021/acs.molpharmaceut.8b00544
   PubMedGoogle Scholar
• Cárcamo-Martínez Á, Domínguez-Robles J, Mallon B, et al. Potential of polymeric films loaded with gold nanorods for local hyperthermia applications. Nanomaterials. 2020;10(3):582. doi: 10.3390/nano10030582
   Web of Science ®Google Scholar
• Barnum L, Samandari M, Schmidt TA, et al. Microneedle arrays for the treatment of chronic wounds. Expert Opin Drug Deliv. 2020 Dec;17(12):1767–1780. doi: 10.1080/17425247.2020.1819787
   PubMed Web of Science ®Google Scholar
• Carter D, van Hoeven N, Baldwin S, et al. The adjuvant GLA-AF enhances human intradermal vaccine responses. Sci Adv. 2018 Sep;4(9):eaas9930. doi: 10.1126/sciadv.aas9930
   PubMed Web of Science ®Google Scholar
• Erdos G, Balmert SC, Carey CD, et al. Improved Cutaneous genetic immunization by microneedle array delivery of an adjuvanted adenovirus vaccine. J Invest Dermatol. 2020 Dec;140(12):2528±. doi: 10.1016/j.jid.2020.03.966
   PubMed Web of Science ®Google Scholar
• Shin JH, Lee JH, Jeong SD, et al. C-di-GMP with influenza vaccine showed enhanced and shifted immune responses in microneedle vaccination in the skin. Drug Deliv Transl Res. 2020 Jun;10(3):815–825. doi: 10.1007/s13346-020-00728-1
   PubMed Web of Science ®Google Scholar
• Weldon WC, Zarnitsyn VG, Esser ES, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One. 2012 Jul 25;7(7):e41501. doi: 10.1371/journal.pone.0041501
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wang F, Yang F, et al. Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant. Vaccine. 2010 Feb 3;28(5):1357–1362. doi: 10.1016/j.vaccine.2009.11.006
   PubMed Web of Science ®Google Scholar
• Stertman L, Palm AE, Zarnegar B, et al. The Matrix-M™ adjuvant: a critical component of vaccines for the 21(st) century. Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885
   PubMed Web of Science ®Google Scholar
• Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018 Jan 29;36(5):668–674. doi: 10.1016/j.vaccine.2017.12.038
   PubMed Web of Science ®Google Scholar
• Ng H-I, Tuong ZK, Fernando GJP, et al. Microprojection arrays applied to skin generate mechanical stress, induce an inflammatory transcriptome and cell death, and improve vaccine-induced immune responses. NPJ Vaccines. 2019 Oct 11;4(1):41. doi: 10.1038/s41541-019-0134-4
   PubMedGoogle Scholar
• Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Delivery Rev. 2012 Nov;64(14):1547–1568. doi: 10.1016/j.addr.2012.04.005
   PubMed Web of Science ®Google Scholar
• Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010 May;17(4):187–207. doi: 10.3109/10717541003667798
   PubMed Web of Science ®Google Scholar
• Márquez-Graña C, Bryan K, Vucen S, et al. Development of a novel single-use microneedle design platform for increased patient compliance. Procedia Manuf. 2017 Jan 1;13:1352–1359.
   Google Scholar
• Baker B, Hacker E, Siller G, et al. Evaluation of the self-administration potential of high-density microarray patches to human skin: a preliminary study. Hum Vaccin Immunother. 2023 Mar 22;19(1):2189409. doi: 10.1080/21645515.2023.2189409
   PubMed Web of Science ®Google Scholar
• Kim JS, J-A C, Kim JC, et al. Microneedles with dual release pattern for improved immunological efficacy of hepatitis B vaccine. Int J Pharm. 2020Dec 15;591:119928.
   PubMedGoogle Scholar
• Na YG, Kim M, Han M, et al. Characterization of hepatitis B surface antigen loaded Polylactic acid-based microneedle and its dermal safety profile. Pharmaceutics. 2020 Jun 9;12(6):531. doi: 10.3390/pharmaceutics12060531
   PubMed Web of Science ®Google Scholar
• Donnelly RF, Singh TRR, Tunney MM, et al. Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro. Pharm Res. 2009 Nov;26(11):2513–2522. doi: 10.1007/s11095-009-9967-2
   PubMed Web of Science ®Google Scholar
• Iredahl F, Muller DA, Togö T, et al. Local response and barrier recovery in elderly skin following the application of high-density microarray patches. Vaccines (Basel). [2022 Apr 10];10(4):583. doi: 10.3390/vaccines10040583
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Anchordoquy TJ, Volkin DB, et al. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021 Mar 1;110(3):997–1001. doi: 10.1016/j.xphs.2020.12.006
   PubMed Web of Science ®Google Scholar
• Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Control Release. 2016 Oct 28;240:135–141. doi: 10.1016/j.jconrel.2015.11.019
   PubMed Web of Science ®Google Scholar
• Marshall S, Sahm LJ, Moore AC. The success of microneedle-mediated vaccine delivery into skin. Hum Vaccin Immunother. 2016;12(11):2975–2983. doi: 10.1080/21645515.2016.1171440
   PubMed Web of Science ®Google Scholar
• Goodson JL, Rota PA. Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.Drug Deliv Transl Res. 2022 May 1;12(5):959–967. doi: 10.1007/s13346-022-01130-9
   PubMed Web of Science ®Google Scholar
• Gavi. The vaccine innovation prioritisation strategy (VIPS) 2021 updated 30 June 2021 cited 2023 Jul 13. Available from: https://www.gavi.org/our-alliance/market-shaping/vaccine-innovation-prioritisation-strategy
   Google Scholar
• Norman JJ, Arya JM, McClain MA, et al. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine. 2014 Apr 1;32(16):1856–1862. doi: 10.1016/j.vaccine.2014.01.076
   PubMed Web of Science ®Google Scholar
• Arya J, Henry S, Kalluri H, et al. Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects. Biomaterials. 2017 Jun;128:1–7.
   PubMed Web of Science ®Google Scholar
• Frew PM, Paine MB, Rouphael N, et al. Acceptability of an inactivated influenza vaccine delivered by microneedle patch: results from a phase I clinical trial of safety, reactogenicity, and immunogenicity. Vaccine. 2020 Oct 21;38(45):7175–7181. doi: 10.1016/j.vaccine.2020.07.064
   PubMed Web of Science ®Google Scholar